N-cyclohexyl-N-methylglycine ethyl ester | 886885-47-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-cyclohexyl-N-methylglycine ethyl ester
• 英文别名: ethyl N-cyclohexyl-N-methylglycinate；ethyl 2-[cyclohexyl(methyl)amino]acetate
• CAS: 886885-47-8
• 化学式: C₁₁H₂₁NO₂
• mdl: MFCD05124193
• 分子量: 199.293
• InChiKey: NKVSJIWDMHRTFM-UHFFFAOYSA-N

物化性质

• 沸点：
  269.4±23.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-cyclohexyl-N-methylglycine ethyl ester 在 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 N-Cyclohexyl-N-methyl-glycin
  参考文献：
  名称：

  PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN

  摘要：

  该发明提供了一种具有角化不全抑制、收缩毛孔或防止/改善粗糙皮肤功能的抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂，不会引起感觉刺激等安全问题，非常安全，并进一步提供了一种外用皮肤组合物，其中添加了具有上述功能的化合物。角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物。外用皮肤组合物包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物，作为上述角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂。

  公开号：

  EP1884230A1
• 作为产物：
  描述：

  (methyl-phenyl-amino)-acetic acid ethyl ester 在 氢气 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 乙醇 为溶剂， 50.0 ℃ 、101.33 kPa 条件下， 以99 %的产率得到N-cyclohexyl-N-methylglycine ethyl ester
  参考文献：
  名称：

  协同催化体系的反应速率加速：芳烃加氢中的金属纳米颗粒和路易斯酸

  摘要：

  由非均相 Rh-Pt 纳米颗粒和路易斯酸组成的协同催化系统极大地加速了芳烃加氢。值得注意的是，含有强给电子基团和空间位阻取代基的特别具有挑战性的底物可以被顺利氢化。

  DOI：

  10.1002/anie.202201203

文献信息

• NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES
  申请人：Cheng Hengmiao

  公开号：US20090093463A1

  公开（公告）日：2009-04-09

  The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及公式(I)的化合物或其药学上可接受的盐：该发明还涉及包含公式(I)化合物的制药组合物，以及治疗通过调节11-β-hsd-1介导的疾病的方法，该方法包括向哺乳动物投与公式(I)化合物的有效量。
• Design, synthesis and binding at cloned muscarinic receptors of N -[5-(1′-substituted-acetoxymethyl)-3-oxadiazolyl] and N -[4-(1′-substituted-acetoxymethyl)-2-dioxolanyl] dialkyl amines
  作者：Stefano Manfredini、Ilaria Lampronti、Silvia Vertuani、Nicola Solaroli、Maurizio Recanatini、David Bryan、Michael McKinney

  DOI：10.1016/s0968-0896(00)00092-4

  日期：2000.7

  Few muscarinic antagonists differentiate between the M-4 and M-2 muscarinic receptors. In a structure-activity study, aimed at discovering leads for the development of a M-4 muscarinic receptor-selective antagonist, we have synthesized and tested at cloned muscarinic receptors the binding of a group of dioxolane- or oxadiazole-dialkyl amines, and compared them to our compound 1, which contains the furan nucleus. Although none of these agents were particularly potent at M-4 receptors (K-d values were typically 30-70 nM), furan derivatives (-)1 and (+)1 were significantly more potent at M-4 receptors than at M-2 receptors (similar to 3- and 4-fold, respectively). The dioxolane derivatives 12b and 12c were more than 10-fold selective for the M-4 versus the M-2 receptors, while the dioxolane derivative 12e was 15-fold more potent at M-4 receptors than for M-2 receptors. However, these agents bound to M-3 receptors with potencies like that for the M-4 receptor, so they are not M-4-selective. The M-4/M-2 relative selectivities of some of our compounds are similar to the better hexahydrosiladifenidol derivatives, and may provide some important structural clues for the development of potent and selective M-4 antagonists. (C) 2000 Elsevier Science Ltd. Ail rights reserved.
• NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES
  申请人：Pfizer, Inc.

  公开号：EP1812407A2

  公开（公告）日：2007-08-01
• [EN] NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES<br/>[FR] NOUVEAUX COMPOSES D'ADAMANTYL AMIDES SUBSTITUES OU NON
  申请人：PFIZER

  公开号：WO2006048750A2

  公开（公告）日：2006-05-11

  [EN] The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-ß-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I).
  [FR] L'invention porte sur des composés de formule (I) et leurs sels pharmacocompatibles, ainsi que sur des procédés de traitement d'états médiés par la modulation du 11-ß-hsd-1, consistant à administrer à un mammifère une quantité efficace du composé de formule (1).
• PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN
  申请人：Shiseido Company, Limited

  公开号：EP1884230A1

  公开（公告）日：2008-02-06

  The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin -inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and to further provide an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor agent, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof. The external composition for skin comprises the one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent.

  该发明提供了一种具有角化不全抑制、收缩毛孔或防止/改善粗糙皮肤功能的抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂，不会引起感觉刺激等安全问题，非常安全，并进一步提供了一种外用皮肤组合物，其中添加了具有上述功能的化合物。角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物。外用皮肤组合物包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物，作为上述角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂。